Oxurion: Developing Innovative Therapies for Diabetic Eye Disease - Patrik De Haes, CEO, Oxurion 00:00:00
CEO Patrik De Haes, MD, explains that Oxurion, formerly ThromboGenics, has developed a portfolio in diabetic eye disease
CEO Patrik De Haes, MD, explains that Oxurion, formerly ThromboGenics, has developed a portfolio in diabetic eye disease